* If you want to update the article please login/register
There are no real-life studies establishing the CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio in the United States. At week 24, we saw a significant decrease in CD8+ T-cell count and an increase in CD4+ T-cell count at week 48. A notable rise in the CD4+ T-cell count in inherited immunodeficiency syndrome-diagnosed patients at week 48, but no significant changes have been made in the CD8+ T-cell count. In patients with controlled immunodeficiency syndrome subgroup and sex or age, dual therapy with DTG plus RPV barely improved the immune status in the first 48 weeks after switching, not just in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count and persistently high rates of viral control.
Source link: https://europepmc.org/article/MED/35713430
We described two HIV/HBV co-infected ACLF patients treated with a HAART regimen containing Dolutegravir and successfully achieved symptoms relief and viral suppression in this case study. Conclusions: The application of DTG in HIV/HBV co-infected patients with ACLF has demonstrated security, providing a concrete scientific basis for future prospective studies.
Source link: https://europepmc.org/article/PPR/PPR506730
By assembling a database of monomeric and dimeric dolutegravir prodrug nanoformulations, ultra-long-acting integrase strand transfer inhibitors were developed. Following single parenteral injection, we show that the physiochemical and pharmacokinetic formulation properties enhance drug release from tissue macrophage depot stores at the muscle injection site and adjacent lymphoid tissues. Prodrug hydrolysis cell sites in tissues are dependent on nanocrystal dissolution and prodrug release, drug-depot volume, perfusion, and cell-tissue pH.
Source link: https://europepmc.org/article/MED/35680875
In a clinical trial in Uganda and South Africa, we compared HRQoL among treatment-na00efve pregnant women randomized to dolutegravir- or efavirenz-based ART. PHS differences in the dolutegravir-based arm were higher in the dolutegravir-based arm, but MHS were more for women in the efavirenz-based armat 24 and 48 weeks. An increase in MHS scores was shown by multivariate analysis, with higher PHS scores when owning a bank account, using the internet, and longer treatment duration all associated with an increase in MHS ratings. Conclusion In late pregnancy, we found no significant differences in HRQoL results among HIV-positive women, from dolutegravir relative to efavirenz. In the first year after delivery, HRQoL roses in HRQoL's first year, the first year has seen more improvements in HRQoL among HIV-positive women who are pregnant late in pregnancy.
Source link: https://europepmc.org/article/MED/35672853
The emergence of beige adipocytes in white AT may play a significant role in reducing excess lipid storage and underlying adipocyte dysfunction while still promoting energy expenditure by boosting energy consumption. In human adipose stromal cells undergoing differentiation and being exposed to dolutegravir, bictegravir, or raltegravir, we were able to determine whether the capacity was assessed in Beiging. Beige differentiation in ASCs was inhibited by reduced expression of beige markers and lower cell respiration, as shown by lower expression of beige markers and lower cell respiration. Our results indicate that hypoxia in fat fibrosis, beiging inhibition, and, eventually, more hypertrophy and related insulin resistance.
Source link: https://europepmc.org/article/MED/35681536
Dolutegravir is currently the most commonly used component of first-line antiretroviral therapy. To measure dolutegravir in dried blood spots, the authors developed and tested a liquid chromatography-ultraviolet detection system. Methods Calibration standards and quality control samples were created by spotting 50 bcl of dolutegravir-spiked whole blood on each circle of DBS cards. DBS from finger prick was collected at 8 time points during 12 hours postdosing, and paired plasma at 1 and 12 hours was used in the clinical pharmacokinetic study. Linearity and Bland-Altman plots were used to determine a correlation between DBS and plasma concentrations. The mean dolutegravir concentration in DBS was 37. 5% lower than that in the plasma, and it was 37. 5% lower than that in the plasma. Plasma concentrations measured and measured plasma samples showed a strong correlation with linearity and Bland-Altman plots, as shown by linearity and Bland-Altman plots. Means of area under curve, Cmax, and C24 from the DBS-derived plasma concentration were 37. 8 mcg/mL, 2. 7 mcg/mL, and 1. 34 mcg/mL, respectively.
Source link: https://europepmc.org/article/MED/34629444
The introduction of HIV-Integrase inhibitors has had a major effect on HIV patients' lives. Around 27. 4 million people are benefitted by antiretroviral therapy since the introduction of the first anti-viral drug, "Azidothymidine," to the latest in inhibitors' advancements. Integrase is one of the new ART targets. Integrase inhibitors' usage has outlasted the use of any other ART due to a strong barrier to resistance and has been touted as the first-line therapy. Inhibitors have been licensed by the U. S. FDA for Raltegravir, Elvitegravir, Dolutegravir, and Bictegravir. ART's high use of ART provided the opportunity to investigate various analytical methods for IN inhibitors. Most studies, according to Literature, are focused on LC-MS/MS/MS and HPLC methods for drug estimation, and only handful of studies recommend spectrophotometric, spectrofluorimetric, and electrochemical techniques. In addition, the study discusses the methods that describe the quantification of integrase drugs in various matrices.
Source link: https://europepmc.org/article/MED/35617468
Background In HIV-1/tuberculosis co-infected patients, there are limited studies comparing the efficacy and safety of raltegravir and dolutegravir to that of efavirenz. We included all HIV-1/tuberculosis co-infected patients beginning antiretroviral therapy with a rifampicin-based approach, with a plasma HIV RNA level of > 1000 copies/mL. The percentage of patients with virological success was the primary endpoint, i. e. In three patients with efavirenz and one patient with raltegravir, there was an emergence of drug resistance in patients with virological failure, defined as a VL > 50 copies/mL. For raltegravir, dolutegravir, and efavirenz, respectively, the rate of treatment discontinuation for drug-related adverse events was 10. 3%, 10. 6%, 16. 9%, respectively. Conclusions In this retrospective cohort analysis, raltegravir and dolutegravir produced similar efficacy and safety findings as efavirenz for the care of HIV-1/TB co-infected patients.
Source link: https://europepmc.org/article/MED/35616997
As first-line therapy for HIV in low- and middle-income countries where tuberculosis is the most common opportunistic disease, Dolutegravir-based regimens are indicated as first-line therapy for HIV. With data from two healthy-volunteer studies and validated it with results from the INSPIRING research, which included HIV-positive individuals, we developed a population pharmacokinetic model of dolutegravir in NONMEM. When 50 or 100 mg once-daily dolutegravir is administered in 70-kg people, 77% and 91. 5%, with a trough concentration above 0. 064 mg/L, respectively, simulations revealed that the protein-adjusted 90% inhibitory concentration reached in 70 percent and 91. 5%. The model, which was derived from healthy-volunteer results, depicts patient health well but underpredicts trough concentrations. However, in the same population, 50 mg of dolutegravir, twice daily, has target concentrations in more than 99% of people cotreated with rifampicin, 100 mg of dolutegravir, once daily, with the intention of achieving satisfactory pharmacokinetic target attainment.
Source link: https://europepmc.org/article/MED/35604212
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions